The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database

Clinical Therapeutics
Najat ZiyadehK Arnold Chan

Abstract

The thiazolidinediones (TZDs), including rosiglitazone maleate and pioglitazone hydrochloride, are commonly prescribed in patients with type 2 diabetes mellitus. Although recent meta-analyses suggest there is an increased risk of myocardial infarction (MI) among rosiglitazone users, these findings were not supported by data from other studies. The goal of this research was to compare the risk of MI, coronary revascularization (CR), and sudden death in patients who began rosiglitazone therapy versus those who began pioglitazone therapy. This was a retrospective cohort study using information from a large health care database (with data available on approximately 14 million individuals). All initiators of rosiglitazone or pioglitazone from July 1, 2000, through March 31, 2007, for whom the first dispensing followed >or=6 months of health plan membership and the member's 18th birthday were identified. The propensity score method was used to create matched cohorts of patients in 3 treatment groups: TZD monotherapy, dual therapy (a TZD plus another antidiabetic agent), and TZD therapy with concomitant insulin. Follow-up continued to a change in treatment regimen, defined as regimen switch (ie, the addition of any antidiabetic agent ...Continue Reading

References

Nov 13, 2002·Pharmacoepidemiology and Drug Safety·Cheryl EngerAlexander M Walker
Jan 15, 2005·Pharmacoepidemiology and Drug Safety·John D SeegerAlexander M Walker
May 27, 2005·Pharmacoepidemiology and Drug Safety·Mark Epstein, UNKNOWN International Society of Pharmacoepidemiology
Jan 5, 2006·Pharmacoepidemiology and Drug Safety·Priscilla VelentgasAlexander M Walker
Jun 7, 2007·Pharmacoepidemiology and Drug Safety·Andrew T McAfeeAlexander M Walker
Aug 9, 2007·Pharmacoepidemiology and Drug Safety·Brian L Strom, James D Lewis
Sep 13, 2007·JAMA : the Journal of the American Medical Association·Sonal SinghCurt D Furberg
Dec 13, 2007·JAMA : the Journal of the American Medical Association·Lorraine L LipscombeDavid A Alter
Apr 3, 2008·Pharmacoepidemiology and Drug Safety·Alexander M WalkerJoan Landon
Jul 10, 2008·Pharmacoepidemiology and Drug Safety·David J MargolisBrian L Strom

❮ Previous
Next ❯

Citations

Oct 28, 2010·Diabetes, Obesity & Metabolism·G Schernthaner, R J Chilton
Jun 12, 2012·Journal of Lipid Research·Janice V HuangGregory G Schwartz
May 24, 2012·Expert Opinion on Drug Safety·Jacqueline Kung, Robert R Henry
Mar 4, 2011·Expert Opinion on Drug Safety·Keith G Tolman
Sep 21, 2010·Diabetes & Metabolism·C GarciaH Mayaudon
Sep 2, 2011·Journal of General Internal Medicine·Nicolas RodondiJacques Cornuz
Aug 18, 2017·Critical Reviews in Toxicology·Melissa A DavidsonDaniel Krewski
Aug 24, 2019·Current Diabetes Reviews·Mayukh BanerjeeNarendra Kumar Pandey
Mar 1, 2017·PPAR Research·Mini ChandraManikandan Panchatcharam
May 2, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Nigel S B Rawson, Carl D'Arcy
Jan 11, 2013·Physiological Reviews·André Tchernof, Jean-Pierre Després

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.